-
Mashup Score: 6
ECHELON-3 trial of ADCETRIS in combination with lenalidomide and rituximab showed significant improvement in primary endpoint of overall survival and in secondary endpoints of progression free survival and overall response rate versus lenalidomide and rituximab plus placebo, regardless of CD30 expression Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo. Positive outcomes were also observed in key secondary endpoints, including progression free survival (PFS) and overall response rate (ORR). The safety and tolerability of
Source: www.pfizer.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 107The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline - 2 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 107The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline - 2 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Patient Case: A 73-Year-Old Woman with Relapsed/Refractory DLBCL - 3 month(s) ago
Expert Matthew Lunning, DO, FACP, reviews the case of a 73-year-old woman with R/R DLBCL, considering current and emerging treatment strategies in this setting.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 105The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline - 3 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 103The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline - 4 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 103The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline - 4 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Article - 4 month(s) ago
INTRODUCTIONThe most common extranodal site of NHL is in the stomach, which represents 30%–40% of all extranodal lymphomas and 55%–65% of all gastrointestinal lymphomas.[1] Primary gastric lymphoma (PGL) is a rare lymphoma and diffuse large B-cell lymphoma (DLBCL) variant accounts for approximately 59% of cases across all subgroups.[2] While the annual incidence is 5–7/100,000 people, age is an…
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
Today, we announced positive topline results from a Phase 3 study in people with relapsed or refractory diffuse large B-cell lymphoma #DLBCL. Learn more: https://t.co/kD4wZ5hAN2 https://t.co/vw09SHqnlP